This is a factual route-comparison explainer. It does not recommend weight-loss injections, assess eligibility, rank NHS or private services, or give treatment or dosing advice.
The short answer
NHS and private weight-loss injection routes can involve authorised prescription medicines, but they are not interchangeable access pathways. NHS access depends on current guidance, commissioned services, prioritisation, and clinical assessment. Private access is paid for outside the NHS route and still requires an accountable prescribing decision; payment does not guarantee a prescription.
The useful comparison is not “free versus fast”. It is how each specific route handles eligibility, assessment, prescribing responsibility, pharmacy supply, total costs, monitoring, continuity, and follow-up.
What differs between the routes?
How NHS access works
NICE technology appraisals set out recommendations for medicines such as tirzepatide and semaglutide in defined circumstances. The criteria and service conditions are medicine-specific; they should be checked in the live guidance rather than inferred from an advert, a diagnosis, or another person’s prescription.
Implementation can be phased. NHS England’s interim commissioning guidance for tirzepatide describes prioritised cohorts and staged implementation across specialist weight-management and primary-care settings. It says people covered by the NICE recommendation should have access within a maximum 12-year implementation period, with the initial three-year cohorts prioritised by clinical need. That is an England implementation document, not a promise of immediate access everywhere in the UK.
- NICE TA1026: tirzepatide recommendations
- NICE TA875: semaglutide recommendations
- NHS England: interim commissioning guidance for tirzepatide
How a private route differs
A private service can operate outside NHS referral and commissioning routes, but it cannot turn a prescription-only medicine into an ordinary retail product. The route should identify who assesses, who prescribes, which pharmacy dispenses, what information is checked, what may cause a prescription to be refused or paused, and who remains responsible for follow-up.
NHS medicine pages state that tirzepatide and semaglutide are available only with a prescription. They also warn people using private routes to use registered pharmacies because fake weight-loss medicines are sold online. For Great Britain pharmacy services, the GPhC register and its weight-management service guidance provide public checks; Northern Ireland uses the Pharmaceutical Society of Northern Ireland register.
- NHS: tirzepatide
- NHS: semaglutide
- GPhC: search the registers
- GPhC: providing weight-management services FAQs
- PSNI: Northern Ireland pharmacy register
Costs are structured differently
NHS and private routes should not be compared using one medicine price alone. On a private route, separate the initial consultation, prescribing, medicine, dispensing, delivery, repeat, monitoring, and follow-up charges. Check cancellation and refund terms, including what happens if the prescriber decides treatment is not appropriate or supply is interrupted.
A low headline price does not establish route quality or long-term affordability. An NHS route may not carry the same direct private fees, but availability, referral, service eligibility, and waiting or prioritisation arrangements can differ. Each claim should be checked with the relevant current service.
Monitoring and continuity
Before starting through either route, it should be clear who reviews progress, side effects, other medicines, relevant changes in health, and whether treatment remains appropriate. The route should also explain how people obtain help between planned reviews and what happens if they move between NHS and private care, change provider, or face a supply interruption.
Do not assume that an NHS clinician will automatically take over prescribing, monitoring, or follow-up started privately. Responsibilities should be agreed by the clinicians and services involved rather than inferred from a private provider’s marketing.
Questions before paying privately
- Who conducts the assessment and who makes the prescribing decision?
- Can the prescriber and dispensing pharmacy be checked on the relevant public registers?
- Is there meaningful two-way clinical communication rather than only a form and checkout?
- Which consultation, prescription, medicine, dispensing, delivery, repeat, monitoring, and follow-up costs are included?
- What happens to fees if no prescription is issued or supply cannot continue?
- Who handles side effects, medicine questions, pauses, supply problems, and ongoing review?
- How are records and responsibilities handled if care later moves to another private provider or the NHS?
Red flags in route comparisons
- Claims that private access is guaranteed, instant, or a shortcut around clinical assessment.
- Claims that NICE eligibility automatically means immediate local NHS access.
- A private price comparison that omits recurring, monitoring, delivery, or follow-up costs.
- No named prescriber, dispensing pharmacy, side-effect contact, or continuity plan.
- Pressure to pay before the assessment, refund terms, and clinical responsibilities are clear.
NHS and private are funding and access routes, not quality ratings. A stronger comparison checks the actual eligibility rules, assessment, prescriber, pharmacy, costs, monitoring, and follow-up behind each route.
What this page is not
- It is not an assessment of eligibility or medicine suitability.
- It is not advice on choosing, starting, stopping, switching, or dosing a medicine.
- It is not a list or ranking of NHS services, private clinics, pharmacies, or medicines.
- It is not a promise of access, prescription, cost, waiting time, or outcome.
- It is not medical, legal, financial, or regulatory advice.